[Mobilisation of haematopoietic stem cells with plerixafor--secondary publication].
Plerixafor (AMD3100) is a selective antagonist of a receptor expressed on haematopoietic stem cells. This receptor normally binds to a ligand on bone marrow stromal cells, responsible for the homing and keeping the stem cells in place. Plerixafor has been successfully used in clinical trails in patients with malignant lymphoma and multiple myeloma, where mobilization of stem cells with granulocyte colony-stimulating factor for leukapheresis and later stem cell transplantation were not possible. Plerixafor has also been given with success to healthy donors for harvest and haematopoietic allograft.
Hansen
Per Boye
PB
Medicinsk Haematologisk Afdeling L, Herlev Hospital, DK-2730 Herlev, Denmark. peboha@heh.regionh.dk
Gaarsdal
Eva
E
D001596:Benzylamines; D000080027:Cyclams; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000494:pharmacology; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D009101:Multiple Myeloma / Q000628:therapy
D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D016179:Granulocyte Colony-Stimulating Factor; C088327:plerixafor